Expertise in
1
conditions

Tsung-hao Liu

National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, TW 
Expertise in
1
conditions
National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, TW 

Overview

Tsung-hao Liu practices practicing medicine in Hsinchu, Taiwan.

Liu is highly rated in 1 condition, according to our data. Their clinical expertise encompasses Liver Cancer, Hepatitis, and Lung Metastases.

They are actively involved in clinical research, co-authoring 25 peer reviewed articles and participating in 2 clinical trials.

Locations

National Taiwan University Hospital Hsin Chu Branch
Hsinchu, TNQ, Taiwan
Other Locations
7 Chung Shan South Road, TPQ 10002, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Atezolizumab Plus Bevacizumab for Patients With Advanced Hepatocellular Carcinoma (HCC) and Chronic Hepatitis B Virus (HBV) Infection
Enrollment Status: Active_not_recruiting
Publish Date: April 09, 2026
Intervention Type: Drug
Study Phase: Not Applicable
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)
Enrollment Status: Completed
Publish Date: July 08, 2024
Intervention Type: Drug
Study Drugs: Nivolumab, Ipilimumab
Study Phase: Phase 2
View 1 Less Clinical Trial

25 Total Publications

Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Atezolizumab plus Bevacizumab versus Lenvatinib as First-Line Treatment for Unresectable Hepatocellular Carcinoma Stratified by the CRAFITY Score: An International Multicenter Study.
Journal: Liver cancer
Published: February 06, 2026

Frequently Asked Questions about Tsung-hao Liu

Is Tsung-hao Liu a top-rated expert for Liver Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Tsung-hao Liu is classified as an Advanced expert for Liver Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Tsung-hao Liu participate in research or clinical trials?

Yes. Tsung-hao Liu has published 25 articles and abstracts on conditions like Liver Cancer. You can view a list of Tsung-hao Liu's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Liu's expertise for a condition
ConditionClose
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile